Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-20-081337
Date:2020-07-01
Issuer: ACCELERON PHARMA INC (XLRN)
Original Submission Date:

Reporting Person:

CELGENE CORP /DE/
86 MORRIS AVENUE
SUMMIT, NJ 07901

Reporting Person:

BRISTOL MYERS SQUIBB CO
430 E. 29TH STREET
14 FLOOR NEW YORK, NY 10016

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-07-01 P 108,108 a $92.50 6,971,772 f2 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 this statement is being filed jointly by celgene corporation and bristol-myers squibb company.
f2 these shares are owned directly by celgene corporation, which is a wholly owned subsidiary of bristol-myers squibb company. bristol-myers squibb company is an indirect beneficial owner of the reported securities.
WhaleWisdom Logo

Elevate your investments